Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT538 + enoblituzumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal, Intravenous
01
Overview
FT538 + enoblituzumab is an investigational combination immunotherapy being evaluated for recurrent ovarian, fallopian tube, and primary peritoneal cancers. **FT538** is an "off-the-shelf" cellular product consisting of natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line. It is genetically engineered with three functional components: a non-cleavable, high-affinity CD16 (hnCD16) receptor to maximize antibody-dependent cellular cytotoxicity (ADCC); a CD38 knockout to enhance metabolic fitness and prevent fratricide; and an IL-15/IL-15 receptor fusion (IL-15RF) to promote activation and persistence without exogenous cytokines. **Enoblituzumab** (MGA271) is an Fc-optimized, humanized monoclonal antibody that targets B7-H3 (CD276), an immune checkpoint molecule frequently overexpressed in solid tumors. In this combination, enoblituzumab binds to B7-H3 on cancer cells, and its optimized Fc region engages the hnCD16 receptor on FT538 cells to trigger potent tumor cell lysis. The combination is currently being studied in a Phase 1 trial (MT2021-27) sponsored by the Masonic Cancer Center, University of Minnesota.
- Other names
- FT538 and EnoblituzumabFT-538 and EnoblituzumabFT 538 and Enoblituzumab
02
Targets
B7-H3FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on FT538 + enoblituzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT538 + enoblituzumab.